Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

Veronika L. Tchesnokova, Elena Rechkina, Lydia Larson, Kendra Ferrier, Jamie Lee Weaver, David W. Schroeder, Rosemary She, Susan M. Butler-Wu, Maria E. Aguero-Rosenfeld, Danielle Zerr, Ferric C. Fang, James Ralston, Kim Riddell, Delia Scholes, Scott Weissman, Kaveri Parker, Brad Spellberg, James R. Johnson, Evgeni V. Sokurenko

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone- sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalClinical Infectious Diseases
Issue number2
StatePublished - Jan 7 2019

Bibliographical note

Funding Information:
Financial support. This work was supported by National Institutes of Health (grant numbers R01AI106007 to E. V. S., and R41AI116114 and R42 AI116114-02 to ID Genomics and E. V. S.); the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (grant number 1 I01 CX000192 01 to J. R. J.); the Partnership for Innovation Award, Group Health Foundation, and Development Fund Award, Group Health Research Institute; and the Gerber Foundation (to E. V. S.).

Funding Information:
Potential conflicts of interest. J. R. J. has received research funding from Achaogen, Allergan, Merck, Syntiron, and Tetraphase; is a consultant for Janssen/Crucell and Syntiron; and has patent applications for tests to detect E. coli strains. V. L. T. and E. V. S. have patent applications to detect E. coli strains. E. V. S. is a major shareholder in ID Genomics. B. S. has received grants and nonfinancial support from Nabriva, Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Ovagene, Bioversys, Acurx, Motif, BioAIM, Synthetic Biologics, Mycomed, and ExBaq. F. C. F. has received grants, personal fees, and nonfinancial support from Cepheid and BioFire; grants and nonfinancial support from ELITech; nonfinancial support from Luminex; and personal fees from the Infectious Diseases Society of America. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.


  • Escherichia coli
  • Fluoroquinolone resistance
  • Urinary tract infections


Dive into the research topics of 'Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193'. Together they form a unique fingerprint.

Cite this